Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
爱文思控股周六报告，宣布由GSK赞助的GALAXIES Lung-201阶段2平台研究的随访中期数据，针对PD-L1高表达的未经治疗、不可切除、局部晚期或转移性患者的Belrestotug+Dostarlimab双联疗法。
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High Non-small Cell Lung Cancer
周六报道，iTEOS Therapeutics公布了由葛兰素史克赞助的GALAXIES Lung-201 2期平台研究的后续中期数据，该研究针对先前未经治疗、不可切除、局部晚期或转移性的 PD-L1 高非小细胞肺癌中的Belrestotug+Dostarlimab doublet
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose.
- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy.
- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations.
- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting
- 使用belrestotug + dostarlimab组合观察到具有临床意义的客观反应率（ORR）为63.3-76.7％，经证实每剂的ORR（CorR）约为60％。
- belrestotug + dostarlimab 与 dostarlimab 单一疗法之间的 CorR 差异超过 30%。
- Belrestotug + dostarlimab的安全性概况与检查点抑制剂组合的已知安全性概况大致一致。
- GALAXIES Lung-301，全球三期注册研究，在相同的适应症和设置下注册
资讯热榜
更新时间